POLY MEDICURE
|
POLY MEDICURE Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 31.78 | 33.41 | 26.91 | 18.69 | 15.28 |
| CEPS(Rs) | 43.04 | 41.62 | 33.52 | 24.64 | 20.90 |
| DPS(Rs) | 3.50 | 3.50 | 3.00 | 3.00 | 2.50 |
| Book NAV/Share(Rs) | 305.72 | 272.72 | 152.82 | 129.17 | 113.24 |
| Tax Rate(%) | 24.97 | 25.18 | 24.98 | 24.51 | 24.96 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 23.24 | 27.17 | 26.07 | 23.88 | 23.19 |
| EBIT Margin(%) | 23.79 | 27.84 | 25.91 | 22.18 | 21.72 |
| Pre Tax Margin(%) | 22.66 | 26.98 | 24.93 | 21.21 | 21.05 |
| PAT Margin (%) | 17.00 | 20.19 | 18.70 | 16.01 | 15.80 |
| Cash Profit Margin (%) | 23.12 | 25.15 | 23.29 | 21.12 | 21.62 |
| Performance Ratios | |||||
| ROA(%) | 8.89 | 12.99 | 14.48 | 11.90 | 11.08 |
| ROE(%) | 10.94 | 16.01 | 19.09 | 15.42 | 14.29 |
| ROCE(%) | 14.05 | 20.37 | 23.63 | 19.10 | 17.42 |
| Asset Turnover(x) | 0.52 | 0.64 | 0.77 | 0.74 | 0.70 |
| Sales/Fixed Asset(x) | 0.93 | 1.15 | 1.19 | 1.22 | 1.22 |
| Working Capital/Sales(x) | 1.38 | 1.08 | 2.82 | 2.18 | 1.67 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.08 | 0.87 | 0.84 | 0.82 | 0.82 |
| Receivable days | 85.20 | 67.43 | 66.78 | 72.05 | 71.34 |
| Inventory Days | 69.58 | 55.13 | 56.78 | 61.45 | 58.03 |
| Payable days | 77.97 | 74.14 | 87.19 | 102.88 | 99.52 |
| Valuation Parameters | |||||
| PER(x) | 37.47 | 67.10 | 59.04 | 51.01 | 62.11 |
| PCE(x) | 27.67 | 53.87 | 47.40 | 38.67 | 45.39 |
| Price/Book(x) | 3.90 | 8.22 | 10.40 | 7.38 | 8.38 |
| Yield(%) | 0.29 | 0.16 | 0.19 | 0.31 | 0.26 |
| EV/Net Sales(x) | 6.57 | 13.62 | 11.10 | 8.17 | 9.98 |
| EV/Core EBITDA(x) | 21.79 | 41.75 | 36.47 | 30.02 | 36.41 |
| EV/EBIT(x) | 27.45 | 48.72 | 42.68 | 36.70 | 45.72 |
| EV/CE(x) | 3.57 | 7.73 | 9.31 | 6.57 | 7.59 |
| M Cap / Sales | 6.44 | 13.61 | 11.08 | 8.20 | 9.86 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 12.30 | 21.37 | 23.36 | 20.82 | 17.37 |
| Core EBITDA Growth(%) | 3.80 | 30.11 | 37.93 | 20.04 | 7.67 |
| EBIT Growth(%) | -3.84 | 30.46 | 44.08 | 23.31 | 5.62 |
| PAT Growth(%) | -5.27 | 31.09 | 44.05 | 22.37 | 7.82 |
| EPS Growth(%) | -4.88 | 24.16 | 44.01 | 22.32 | 7.80 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.11 | 0.06 | 0.12 | 0.12 | 0.12 |
| Current Ratio(x) | 3.05 | 4.39 | 2.15 | 2.46 | 3.46 |
| Quick Ratio(x) | 2.40 | 3.77 | 1.63 | 1.87 | 2.71 |
| Interest Cover(x) | 20.96 | 32.59 | 26.38 | 22.87 | 32.68 |
| Total Debt/Mcap(x) | 0.03 | 0.01 | 0.01 | 0.02 | 0.01 |
Compare Financial Ratios of peers of POLY MEDICURE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| POLY MEDICURE | ₹17,616.7 Cr | 2.2% | -4.2% | -13.4% | Stock Analytics | |
| LENSKART SOLUTIONS | ₹118,577.0 Cr | -0.9% | 14.3% | NA | Stock Analytics | |
| 3B BLACKBIO DX | ₹1,222.1 Cr | -6.4% | 16.5% | -0.8% | Stock Analytics | |
| LAXMI DENTAL | ₹1,111.3 Cr | 2.1% | -2% | -39.2% | Stock Analytics | |
| PREVEST DENPRO | ₹488.5 Cr | 3.9% | 4.4% | -31.7% | Stock Analytics | |
| NURECA | ₹319.4 Cr | 3.6% | -2.8% | 35.9% | Stock Analytics | |
POLY MEDICURE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| POLY MEDICURE | 2.2% |
-4.2% |
-13.4% |
| SENSEX | -2.3% |
-4.1% |
-7.4% |
You may also like the below Video Courses
